SANOFI Pasteur, the French pharmaceutical manufacturer of the controversial anti-dengue vaccine that was given to more than 800,000 individuals, most of them children, in the Philippines declined both requests by the government to fully refund the used doses and finance medical treatment of first-time dengue patients who were allegedly exposed to the risks of the drug.

In an e-mailed statement on Monday, Sanofi said if they agreed to fully reimburse the used vials of Dengvaxia, this would imply that the vaccine was “ineffective.”

Premium + Digital Edition

Ad-free access


P 80 per month
(billed annually at P 960)
  • Unlimited ad-free access to website articles
  • Limited offer: Subscribe today and get digital edition access for free (accessible with up to 3 devices)

TRY FREE FOR 14 DAYS
See details
See details